Melissa Epperly - 10 Feb 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Financial Officer
Signature
By: /s/ Melissa B. Epperly
Issuer symbol
ZNTL
Transactions as of
10 Feb 2022
Transactions value $
$0
Form type
4
Filing time
14 Feb 2022, 20:09:47 UTC
Previous filing
04 Oct 2021
Next filing
23 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Award $0 +16,405 +6.56% $0 266,407 10 Feb 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Award $0 +38,489 $0 38,489 10 Feb 2022 Common Stock 38,489 $52.61 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
F2 The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.